PURPOSE: To determine (a) how often the Breast Imaging Reporting and Data System (BI-RADS) category 3 was used in the American College of Radiology Imaging Network (ACRIN) Digital Mammographic Imaging Screening Trial (DMIST), either at the time of screening mammography or after work-up, (b) how often subjects actually returned for the recommended follow-up examination, and (c) the rate and stages of any malignancies subsequently found in subjects for whom short-term interval follow-up was recommended. MATERIALS AND METHODS: This study was approved by the Institutional Review Board at all institutions where subjects were enrolled. All subjects participating in DMIST gave informed consent and the study was HIPAA-compliant. A total of 47,599 DMIST-eligible and evaluable subjects, all of whom consented to undergo both digital and screen-film mammography, were included in this analysis. Cases referred for short-term interval follow-up based on digital, screen-film, or both imaging examinations were determined. Compliance with the recommendations and the final outcome (malignancy diagnosis at biopsy or no malignancy confirmed through follow-up) of each evaluable case were determined. RESULTS: A total of 1114 of the 47,599 (2.34%) subjects had tumors assigned a BI-RADS 3 category and were recommended to undergo short-interval follow-up. In this study, 791 of 1114 (71%) of the subjects were compliant with the recommendation and returned for short-interval follow-up. Of the women who did not return for short-interval follow-up, 70% (226 of 323) did return for their next annual mammography. Among all subjects whose tumors were assigned a BI-RADS 3 category either at screening mammography or after additional work-up, nine of 1114 (0.81%) were found to have cancer. Of the nine biopsy-proved cancers, six were invasive cancers and three were ductal carcinoma in situ stage Tis-T1c. The invasive cancers were all less than 2 cm in size. CONCLUSION: In DMIST, radiologists used the BI-RADS 3 classification infrequently (2.3% of patients). Tumors assigned a BI-RADS 3 category had a low rate of malignancy. The relatively high rate of noncompliance with short-interval follow-up recommendations (323 of 1114, or 29%) supports prior recommendations that radiologists thoroughly evaluate lesions before placing them in this category.
PURPOSE: To determine (a) how often the Breast Imaging Reporting and Data System (BI-RADS) category 3 was used in the American College of Radiology Imaging Network (ACRIN) Digital Mammographic Imaging Screening Trial (DMIST), either at the time of screening mammography or after work-up, (b) how often subjects actually returned for the recommended follow-up examination, and (c) the rate and stages of any malignancies subsequently found in subjects for whom short-term interval follow-up was recommended. MATERIALS AND METHODS: This study was approved by the Institutional Review Board at all institutions where subjects were enrolled. All subjects participating in DMIST gave informed consent and the study was HIPAA-compliant. A total of 47,599 DMIST-eligible and evaluable subjects, all of whom consented to undergo both digital and screen-film mammography, were included in this analysis. Cases referred for short-term interval follow-up based on digital, screen-film, or both imaging examinations were determined. Compliance with the recommendations and the final outcome (malignancy diagnosis at biopsy or no malignancy confirmed through follow-up) of each evaluable case were determined. RESULTS: A total of 1114 of the 47,599 (2.34%) subjects had tumors assigned a BI-RADS 3 category and were recommended to undergo short-interval follow-up. In this study, 791 of 1114 (71%) of the subjects were compliant with the recommendation and returned for short-interval follow-up. Of the women who did not return for short-interval follow-up, 70% (226 of 323) did return for their next annual mammography. Among all subjects whose tumors were assigned a BI-RADS 3 category either at screening mammography or after additional work-up, nine of 1114 (0.81%) were found to have cancer. Of the nine biopsy-proved cancers, six were invasive cancers and three were ductal carcinoma in situ stage Tis-T1c. The invasive cancers were all less than 2 cm in size. CONCLUSION: In DMIST, radiologists used the BI-RADS 3 classification infrequently (2.3% of patients). Tumors assigned a BI-RADS 3 category had a low rate of malignancy. The relatively high rate of noncompliance with short-interval follow-up recommendations (323 of 1114, or 29%) supports prior recommendations that radiologists thoroughly evaluate lesions before placing them in this category.
Authors: Etta D Pisano; R Edward Hendrick; Martin J Yaffe; Janet K Baum; Suddhasatta Acharyya; Jean B Cormack; Lucy A Hanna; Emily F Conant; Laurie L Fajardo; Lawrence W Bassett; Carl J D'Orsi; Roberta A Jong; Murray Rebner; Anna N A Tosteson; Constantine A Gatsonis Journal: Radiology Date: 2008-02 Impact factor: 11.105
Authors: R Edward Hendrick; Elodia B Cole; Etta D Pisano; Suddhasatta Acharyya; Helga Marques; Michael A Cohen; Roberta A Jong; Gordon E Mawdsley; Kalpana M Kanal; Carl J D'Orsi; Murray Rebner; Constantine Gatsonis Journal: Radiology Date: 2008-04 Impact factor: 11.105
Authors: Shagufta Yasmeen; Patrick S Romano; Mary Pettinger; Rowan T Chlebowski; John A Robbins; Dorothy S Lane; Susan L Hendrix Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: K Robin Yabroff; Nancy Breen; Sally W Vernon; Helen I Meissner; Andrew N Freedman; Rachel Ballard-Barbash Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-05 Impact factor: 4.254
Authors: Ximena Varas; José H Leborgne; Francisco Leborgne; Julieta Mezzera; Sylvia Jaumandreu; Felix Leborgne Journal: AJR Am J Roentgenol Date: 2002-09 Impact factor: 3.959
Authors: Janice S Sung; Lizza Lebron; Delia Keating; Donna D'Alessio; Christopher E Comstock; Carol H Lee; Malcolm C Pike; Miranda Ayhan; Chaya S Moskowitz; Elizabeth A Morris; Maxine S Jochelson Journal: Radiology Date: 2019-08-27 Impact factor: 11.105
Authors: Prithwijit Roychowdhury; Gopal R Vijayaraghavan; John Roubil; Imani M Williams; Efaza Siddiqui; Srinivasan Vedantham Journal: Biomed J Sci Tech Res Date: 2022-02-14
Authors: Anna Linda; Chiara Zuiani; Viviana Londero; Eleonora Di Gaetano; Anna Dal Col; Rossano Girometti; Massimo Bazzocchi Journal: Radiol Med Date: 2013-12-03 Impact factor: 3.469
Authors: Andrea Botticelli; Eva Mazzotti; Domenica Di Stefano; Viviana Petrocelli; Federica Mazzuca; Marco La Torre; Francesca Romana Ciabatta; Rosaria Maria Giovagnoli; Paolo Marchetti; Adriana Bonifacino Journal: J Ultrasound Date: 2015-08-12